Literature DB >> 16393327

Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge.

E M Erin1, A S Zacharasiewicz, G C Nicholson, A J Tan, L A Higgins, T J Williams, R D Murdoch, S R Durham, P J Barnes, T T Hansel.   

Abstract

BACKGROUND: Cytokines and chemokines produced by allergen-reactive T-helper type 2 (Th2) cells may be pivotal to the pathophysiology of allergic disorders.
OBJECTIVE: This study was performed to assess the effect of 7 days of topical corticosteroid on nasal allergen challenge (NAC) in terms of eosinophils, cytokines and chemokines obtained by nasal lavage and filter paper methods.
METHODS: Patients with grass pollen seasonal-allergic rhinitis (n = 13) out of season received nasal challenge following matched placebo (twice daily into each nostril for 7 days) and fluticasone propionate (100 microg twice daily into each nostril for 7 days). Chemokine and cytokine levels were analysed using a sensitive automated bead immunoassay system at intervals up to 8 h after NAC.
RESULTS: Levels of cytokines and chemokines from filter paper were generally higher than from nasal lavage. Fluticasone propionate caused a reduction in symptoms, total leukocyte counts and eosinophils, and abrogation of IL-4, IL-5, IL-6 and IL-13 responses in the filter paper taken in the late phase (P < 0.05 for IL-4 and IL-13, P < 0.01 for IL-5 and IL-6). Levels of chemokines (eotaxin, RANTES, MCP-1, MIP-1alpha, IL-8 and IP-10) were also reduced in the late phase (P < 0.01 at 8 h). However, levels of IL-2, IL-3, IL-7, IL-12 (p40 and p70), -15, TNF-alpha, IFN-gamma and GM-CSF were not affected.
CONCLUSION: Fluticasone propionate has selective inhibitory effects on Th2 cytokine synthesis following nasal challenge, while also decreasing release of chemokines, but not affecting levels of Th1 cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16393327     DOI: 10.1111/j.1365-2222.2005.02381.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  26 in total

1.  [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].

Authors:  L Klimek; P Högger; O Pfaar
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

2.  A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.

Authors:  Peter Hodsman; Claire Ashman; Anthony Cahn; Erika De Boever; Nicholas Locantore; Adrian Serone; Isabelle Pouliquen
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 3.  Cytokine profiles in allergic rhinitis.

Authors:  Guy Scadding
Journal:  Curr Allergy Asthma Rep       Date:  2014-05       Impact factor: 4.806

4.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

5.  Comprehensive profiling of peripheral immune cells and subsets in patients with intermittent allergic rhinitis compared to healthy controls and after treatment with glucocorticoids.

Authors:  Huan Zhang; Lars Olaf Cardell; Janne Bjorkander; Mikael Benson; Hui Wang
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

6.  Quantitative expression of osteopontin in nasal mucosa of patients with allergic rhinitis: effects of pollen exposure and nasal glucocorticoid treatment.

Authors:  Serena E O'Neil; Carina Malmhäll; Konstantinos Samitas; Teet Pullerits; Apostolos Bossios; Jan Lötvall
Journal:  Allergy Asthma Clin Immunol       Date:  2010-11-02       Impact factor: 3.406

Review 7.  Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.

Authors:  G W Canonica; E Compalati
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

Review 8.  Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis.

Authors:  M Okano
Journal:  Clin Exp Immunol       Date:  2009-08-06       Impact factor: 4.330

9.  Allergen-IgE complexes trigger CD23-dependent CCL20 release from human intestinal epithelial cells.

Authors:  Hongxing Li; Mirna Chehade; Weicheng Liu; Huabao Xiong; Lloyd Mayer; M Cecilia Berin
Journal:  Gastroenterology       Date:  2007-09-25       Impact factor: 22.682

10.  Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments.

Authors:  Gesmar Rs Segundo; Fabíola A Gomes; Karla P Fernandes; Ronaldo Alves; Deise Ao Silva; Ernesto A Taketomi
Journal:  Biologics       Date:  2009-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.